跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Y-101
首页
药物
Y-101
Y-101
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
2-iminopyrrolidine derivatives
US 7244730 B2
申请人: EISAI CO LTD
优先权: 2001
CN
US
4 件公开
Water-soluble azo compound or salt thereof, ink composition, and colored body
US 8506697 B2
申请人: MORITA RYOUTAROU
优先权: 2010
US
2 件公开
Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif)
US 2006106102 A1
申请人: MORAND ERIC F
优先权: 2002
US
Porphyrin-phthalocyanine dimer and tetramer having directly-bound Pi electron systems and production method thereof
US 2006217538 A1
申请人: KOBUKE YOSHIAKI
优先权: 2003
US
5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
CN 101305000 A
申请人: JANSSEN PHARMACEUTICA NV
优先权: 2005
CN
US 2007060577 A1
申请人: PLAYER MARK R
优先权: 2006
US
US 2008114007 A1
申请人: PLAYER MARK R
优先权: 2007
US
Optimized expression of HPV31 L1 in yeast
US 7276243 B2
申请人: MERCK & CO INC
优先权: 2005
US
BICYCLIC HETEROCYCLIC COMPOUND
EP 1961745 A1
申请人: ONO PHARMACEUTICAL CO
优先权: 2006
EP
COMPOUNDS, MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES, ORGANIC ELECTROLUMINESCENT DEVICES, AND ELECTRONIC DEVICES
EP 4174073 A1
申请人: IDEMITSU KOSAN CO
优先权: 2020
EP
Radiopharmaceutical targeting urokinase-type plasminogen activator receptor
CN 117794950 A
申请人: POLARIS MEDICAL TECH LLC
优先权: 2021
CN
药物
反馈